Posted by Michael Wonder on 17 May 2018
Amgen receives European Commission Approval for Repatha (evolocumab) to prevent heart attack and stroke in adults with established cardiovascular disease
16 May 2018 - Amgen announces efforts to improve Repatha's affordability across Europe for payers who significantly expand patient access.
Amgen today announced that the European Commission has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels.
With the expanded label now in place, Amgen is working with payers in Europe to remove prescribing barriers and expand access in order to reach patients with established cardiovascular disease who are at risk of another event.
